武汉回盛生物科技股份有限公司 内幕信息知情人登记管理制度 第一章 总 则 第五条 公司董事、监事及高级管理人员和公司各部门、子公司、分公司都 应做好内幕信息的保密工作。 第六条 公司董事、监事、高级管理人员及内幕信息知情人不得泄露内幕信 息，不得进行内幕交易或配合他人操纵证券交易价格。 第一条 为进一步规范武汉回盛生物科技股份有限公司（以下简称"公司"） 内幕信息管理行为，加强内幕信息保密工作，维护公司信息披露的公平、公正、 公开原则，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司信息披露管理 办法》《上市公司监管指引第 5 号——上市公司内幕信息知情人登记管理制度》 《深圳证券交易所创业板股票上市规则》（以下简称"《股票上市规则》"）、 《深圳证券交易所上市公司自律监管指引 2 号——创业板上市公司规范运作》 （以下简称"《创业板上市公司规范运作》"）、《深圳证券交易所上市公司自 律监管指引第 5 号——信息披露事务管理》（以下简称"《信息披露事务管理》"） 以及《武汉回盛生物科技股份有限公司章程》（以下简称"《公司章程》"）的 有关 ...

| | | 往来方与上 | | 年期 2023 | 2023 年半年 度往来累计 | 2023 年半 年度往来 | 年半 2023 | 年 2023 6 | | 往来性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 其他关联资金往来 | 资金往来方名称 | 市公司的关 | 上市公司核算 | 初往来资金 | 发生金额 | 资金的利 | 年度偿还累 | 月末往来 | 往来形成原 | （经营性往 | | | | | 的会计科目 | | | | | | 因 | 来、非经营性 | | | | 联关系 | | 余额 | （不含利 | 息（如 | 计发生金额 | 资金余额 | | 往来） | | | | | | | 息） | 有） | | | | | | 控股股东、实际控 制人及其附属企业 | - | - | - | - | - | - | - | - | - | - | | | - | - | - | - | - | - | - | - | - | - | | | 湖北回盛生物科 技有限公司 | 子公司 | 其他应收款 | ...

| 证券代码：300871 | 证券简称：回盛生物 | 公告编号：2023-055 | | --- | --- | --- | | 转债代码：123132 | 转债简称：回盛转债 | | 武汉回盛生物科技股份有限公司董事会 关于 2023 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 根据《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求（2022 年 修订）》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引 第 2 号——创业板上市公司规范运作》《深圳证券交易所创业板上市公司自律监管指南第 2 号——公告格式》之"第 21 号上市公司募集资金年度存放与使用情况的专项报告格式" 等有关规定，武汉回盛生物科技股份有限公司（以下简称"公司"或"本公司"）董事会编 制了 2023 年半年度募集资金存放与使用情况的专项报告。 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 1、首次公开发行股票募集资金 经中国证券监督管理委员会《关于同意武汉回盛生物科技股份有限公司首次公开发 ...

武汉回盛生物科技股份有限公司 总经理轮值制度 第一条 目的 为更好适应武汉回盛生物科技股份有限公司（以下简称"公司"）经营发展需要， 培养高素质管理团队，不断推进公司的高质量、可持续发展，根据《中华人民共 和国公司法》《中华人民共和国证券法》等法律法规和《武汉回盛生物科技股份 有限公司章程》（以下简称"《公司章程》"）和《武汉回盛生物科技股份有限公司 总经理工作细则》（以下简称"《总经理工作细则》"）的有关规定，特制定本制度。 第二条 轮值制度 公司实行总经理轮值制度，设置轮值总经理一名，全面负责公司生产经营管 理工作。 第三条 轮值人选范围 轮值总经理人选范围为在公司任职的非独立董事或公司高级管理人员中选任。 第四条 轮值总经理职责 公司实行董事会领导下的总经理轮值制度。轮值总经理根据《总经理工作细 则》的规定履行总经理相应职责，并承担相关法律法规及公司制度规定的义务。 轮值总经理对董事会负责，行使下列职权： 1、主持公司日常经营与管理工作，组织实施董事会的决议、公司年度经营计 划和投资方案，并向董事会报告工作； 2、拟订公司中长期发展规划与年度生产经营计划； 5、拟订公司内部管理机构设置方案； 6、拟订公 ...

| 证券代码：300871 | 证券简称：回盛生物 | 公告编号：2023-051 | | --- | --- | --- | | 转债代码：123132 | 转债简称：回盛转债 | | 武汉回盛生物科技股份有限公司 第三届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 武汉回盛生物科技股份有限公司（以下简称"公司"）第三届董事会第五 次会议于 2023 年 8 月 28 日在公司会议室以现场方式召开，本次会议通知于 2023 年 8 月 18 日以电子邮件及电话方式送达全体董事。本次应出席董事 5 名， 实际出席会议的董事 5 名。本次会议由董事长张卫元先生主持，公司监事会成 员和高级管理人员列席了本次会议，会议的召集、召开和表决程序符合有关法 律、行政法规、部门规章、规范性文件和《公司章程》的规定。 二、董事会会议审议情况 经与会董事认真审议，通过了以下议案： （一）审议通过了《关于<2023 年半年度报告>及其摘要的议案》 公司董事会在全面审核公司《2023 年半年度报告》及其摘要后，一致认 为：公司 2 ...

武汉回盛生物科技股份有限公司 总经理工作细则 第一章 总则 第一条 为进一步完善武汉回盛生物科技股份有限公司（以下简称"公司"） 的治理结构和经营运作体系，促进经营管理的制度化、规范化、科学化，依照《中 华人民共和国公司法》（以下简称"《公司法》"）、《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》《武汉回盛生物科技股份有限公 司章程》（以下简称"《公司章程》"）的有关规定，并结合公司实际情况，制定本 细则。 1、具备高度的敬业精神，全力履行好自己的职责，忠实地维护公司利益； 第二条 公司依法设置总经理和副总经理、财务总监、审计总监、人力资 源总监、技术服务总监、董事会秘书等高级管理人员（以下简称"高管"），高管 应当遵守法律、行政法规和《公司章程》的规定，履行诚信和勤勉的义务，高 管在就任时应签订《上市公司高级管理人员声明及承诺书》。总经理对公司董事 会负责并报告工作，副总经理、财务总监等高管对总经理负责并报告工作。在 总经理不能履行职权时，由董事长或董事长指定一名副总经理代行职权。 第二章 总经理的任免 第三条 总经理任职，应当具备下列条件： （一）个人品质：有较强的责任心，积 ...

证券代码：300871 证券简称：回盛生物 转债代码：123132 转债简称：回盛转债 武汉回盛生物科技股份有限公司 投资者关系活动记录表 编号：2023-003 特定对象调研 分析师会议 媒体采访 业绩说明会 投资者关系 新闻发布会 路演活动 活动类别 现场参观 其他（2023 年湖北辖区上市公司投资者网上集体接待日） 参与单位名称 通过全景路演网络平台参加 2023 年湖北辖区上市公司投资者网上集体接 待日活动的投资者 时 间 2023 年 5 月 25 日 14:30-16:35 地 点 全景网"投资者关系互动平台"（https://ir.p5w.net）网络文字互动 副总经理、财务总监 杨凯杰 董事会秘书 王庆峰 上市公司 接待人员姓名 公司就投资者在本次说明会中提出的问题进行了回复： 1、贵公司泰乐菌素生产开工率达到多少？ 回复：尊敬的投资者，您好！目前公司泰乐菌素生产线开工率 40% 多，正处于爬坡阶段。谢谢！ 投资者关系活动 2、公司宠物制剂产线终止，后续宠物药品生产是外代工吗？ 主要内容介绍 回复：尊敬的投资者，您好！目前公司子公司湖北回盛"片剂/颗粒 剂（含中药提取）"生产线已通过 GMP ...

Group 1: Company Overview and Market Position - Wuhan Huisheng Biological Technology Co., Ltd. specializes in veterinary pharmaceuticals, including chemical preparations, raw materials, and traditional Chinese medicine preparations, with a focus on high-tech innovation [2] - The company has obtained 154 veterinary drug approval documents, with products widely used in swine, poultry, aquaculture, ruminants, and pets [3] - The company has maintained a zero non-compliance rate in veterinary drug quality supervision checks for 11 consecutive years from 2012 to 2022 [3] Group 2: Research and Development Initiatives - The company focuses on addressing major epidemic issues, developing innovative products, and enhancing service efficiency for breeding enterprises [3] - In 2022, the company had 104 research projects and submitted 5 new veterinary drug registration applications to the Ministry of Agriculture and Rural Affairs, with one product receiving approval in April 2023 [3] - The company has developed several innovative products, including the fourth-generation antibiotic "Taidiluo" and a third-generation oral cephalosporin, which have become key brand features [3] Group 3: Financial Performance and Market Trends - In Q1 2023, the company's operating income increased by 12.03% compared to the same period last year, with a gross profit margin growth of 4.01% [7] - The company anticipates improved market conditions in the second half of the year due to the recovery of the breeding industry and decreasing production costs of new raw material projects [4] - The company has faced a decline in performance in 2022 due to weak downstream market demand and fluctuations in raw material prices [6] Group 4: Sales Strategy and Customer Engagement - The company has established a marketing network combining direct sales to group clients and distributor channels, enhancing customer coverage [6] - The sales proportion from group clients is increasing, reflecting the growing recognition of the company's products among large breeding groups [5] - The company aims to expand its high-margin product sales and improve operational efficiency to counteract pricing pressures from group clients [5] Group 5: Future Growth and Development Plans - The company plans to enhance its technological content and focus on developing high-efficiency, low-residue veterinary drugs to improve disease prevention and animal welfare [7] - The integration of raw material and preparation production is expected to become a new growth point for the company [8] - The company is actively working on 20 pet drug projects, with several major products in development [5]

Financial Performance - In 2022, the company achieved operating revenue of 1,022.90 million CNY, a year-on-year increase of 2.68%, while net profit attributable to shareholders was 52.71 million CNY, a decrease of 60.33% compared to the previous year [3] - In Q4 2022, the company reported operating revenue of 351.42 million CNY, a year-on-year growth of 40.40% and a quarter-on-quarter increase of 28.04%. Net profit for the same period was 26.30 million CNY, showing a year-on-year increase of 100.21% and a quarter-on-quarter increase of 32.21% [3] - In Q1 2023, the company achieved operating revenue of 230.41 million CNY, a year-on-year increase of 12.03%, with net profit reaching 14.86 million CNY, a significant year-on-year growth of 634.03% [3] Product Development and Market Position - As of the end of 2022, the company had obtained 154 veterinary drug approval numbers, focusing on pig medications while also covering poultry, aquaculture, pets, and ruminants [4] - The company successfully launched a new antibiotic, "Taidiloxin Injection," which is a broad-spectrum, high-efficiency, and low-toxicity animal-specific antibacterial drug [4] - The company has made progress in its raw material and formulation integration strategy, achieving a revenue of 113 million CNY from raw materials, accounting for 11.11% of total revenue, with a year-on-year growth of 69% [3] Research and Development - By the end of 2022, the company had 113 R&D personnel, an increase of 12.71% year-on-year, and had made significant upgrades in hardware conditions and project management [4] - The company has 104 ongoing research projects and submitted five new veterinary drug registration applications to the Ministry of Agriculture and Rural Affairs [4] - The company is focusing on innovative drug development, with several new veterinary drugs in the pipeline, including a new drug for aquaculture that has completed toxicology trials [4] Challenges and Strategic Responses - The company faced challenges in 2022 due to a downturn in the pig farming industry, leading to weak demand for veterinary drugs and a decline in overall gross margin [5] - To enhance profitability, the company plans to improve customer coverage and penetration, leverage high-end technical services, and increase the sales proportion of high-margin products [5] - The company has expanded its client base, achieving coverage of the top 10 domestic pig farming enterprises and plans to strengthen communication with clients to enhance service and loyalty [5]

Business Focus - The company focuses on veterinary medicine, primarily in the pig medication sector, with sales revenue and operating profit mainly derived from this segment [5]. - The veterinary medicine industry is transitioning to a high-quality development stage, with increased focus on innovative and effective antimicrobial drugs [33]. - The scale of livestock farming in China has exceeded 70%, leading to increased concentration in the veterinary medicine industry [34]. - The company has established itself among the top 10 in the domestic pig breeding industry and maintains stable partnerships with numerous large-scale breeding enterprises [37]. - The company has obtained 154 veterinary drug approval numbers, with products widely used across various animal sectors including pigs, poultry, aquaculture, ruminants, and pets [38]. Financial Performance - The company's operating revenue for 2022 was ¥1,022,900,792.34, representing a 2.68% increase compared to ¥996,216,817.61 in 2021 [24]. - The net profit attributable to shareholders for 2022 was ¥52,706,475.48, a decrease of 60.33% from ¥132,865,534.22 in 2021 [24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥44,089,151.68, down 61.74% from ¥115,223,691.93 in 2021 [24]. - The net cash flow from operating activities decreased by 37.91% to ¥96,680,490.85 in 2022 from ¥155,718,489.99 in 2021 [24]. - The total assets at the end of 2022 were ¥2,989,114,303.25, an increase of 9.03% from ¥2,741,662,030.01 at the end of 2021 [24]. Risks and Challenges - The company faces risks from fluctuations in downstream industry demand, particularly in the pig breeding sector, which can impact overall demand for veterinary products [5]. - The company is exposed to risks from significant fluctuations in raw material prices, which directly affect the cost of veterinary drug formulations [6]. - The company has achieved certain success in controlling African swine fever, but any resurgence could negatively impact the pig breeding industry and, consequently, the demand for veterinary products [9]. Research and Development - The company is actively increasing R&D investment in pet medications and expanding market channels to tap into the pet medicine market [36]. - The company has completed the development of 10 new functional pet health products and submitted 10 national patent applications [74]. - The company has established a new independent R&D institution with a registered capital of CNY 10 million to enhance technological innovation [69]. - The company has established partnerships with academic institutions to enhance its research capabilities and drive technological advancements in its product lines [137]. Marketing and Sales Strategy - The marketing strategy has shifted from a "product-oriented" approach to a "value-oriented" approach, focusing on market pain points and improving breeding efficiency [53]. - The company has implemented a production management model combining sales-based production and safety stock, ensuring adequate supply for high-demand products [45]. - The company has adopted a direct sales and distribution model, signing annual cooperation agreements with both large-scale breeding groups and small-scale farmers [45]. Governance and Compliance - The company’s financial report has been verified for accuracy and completeness by its board and management, ensuring transparency for investors [3]. - The governance structure includes a complete system with a general meeting of shareholders, board of directors, supervisory board, and management team, ensuring clear functional roles [128]. - The company has not reported any significant discrepancies in governance compared to legal and regulatory requirements [121]. - The company has a dedicated investor relations section on its official website to maintain good communication with investors [121]. Employee and Management - The total number of employees at the end of the reporting period is 957, with 336 in the parent company and 621 in major subsidiaries [155]. - The company has a strong emphasis on performance-based remuneration for its senior management [144]. - The company has implemented a stock incentive plan to align the interests of management with those of shareholders, which includes the repurchase and cancellation of shares [133]. Environmental and Social Responsibility - The company has actively responded to national carbon peak and carbon neutrality initiatives by optimizing processes to reduce energy consumption and utilizing rooftop resources for photovoltaic power generation [176]. - The company emphasizes strict compliance with environmental regulations and has implemented measures to reduce resource consumption and environmental impact during production [182]. - The company has not engaged in any significant environmental violations or received administrative penalties during the reporting period [176]. Future Outlook - The company aims to achieve breakthroughs in poultry, ruminants, and aquaculture while consolidating its advantages in pig medications [36]. - The company plans to enhance its R&D capabilities, focusing on traditional Chinese veterinary medicine and biological veterinary medicine, to develop new drugs with its own branding [111]. - The company anticipates a gradual recovery in market conditions, projecting improved financial performance in the upcoming fiscal year [136].